share_log
Reuters ·  Jan 6 23:00
Pharmaessentia Announces Positive Topline Phase 3 Data From Surpass-Et Study Evaluating Ropeginterferon Alfa-2B-Njft (P1101) for Essential Thrombocythemia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment